NASDAQ
32.43USD
+0.26 (+0.81%)
Dots are scored news catalysts — size = impact, color = sentiment. Tap one to read it.
Market cap
2B
P/E
—
EPS
—
Beta
-1.01
52W range
13.5-44.6
Day range
31.66–33.08
Open
32.85
Prev close
32.17
Volume
264.1K
Avg volume
780.5K
Dividend
0.00
IPO
2024-09-13
https://seekingalpha.com/article/4921888-zenas-biopharma-obexelimab-could-build-an-autoimmune-franchise · 7/14/2026+0.90
https://www.fool.com/coverage/filings/2026/06/21/zenas-biopharma-s-ceo-purchased-60-000-company-shares-here-s-a-deeper-look-at-the-transaction/ · 6/21/2026+0.40
https://www.globenewswire.com/news-release/2026/06/02/3305741/0/en/Zenas-BioPharma-Announces-Data-from-the-Registrational-Phase-3-INDIGO-Trial-of-Obexelimab-in-Immunoglobulin-G4-Related-Disease-IgG4-RD-Simultaneously-Presented-at-the-EULAR-2026-Co.html · 6/2/2026+1.00
https://www.globenewswire.com/news-release/2026/05/13/3293817/0/en/Zenas-BioPharma-Announces-First-Subject-Dosed-in-Phase-1-Clinical-Trial-of-ZB021-a-Novel-Potentially-Best-in-Class-Oral-IL-17AA-AF-Inhibitor.html · 5/13/2026
https://www.globenewswire.com/news-release/2026/03/31/3265900/0/en/Portnoy-Law-Firm-Announces-Class-Action-on-Behalf-of-Aldeyra-Therapeutics-Inc-Investors.html · 3/31/2026-0.20
https://www.defenseworld.net/2026/03/28/zenas-biopharma-nasdaqzbio-versus-twist-bioscience-nasdaqtwst-critical-analysis.html · 3/28/2026+0.00
https://www.globenewswire.com/news-release/2026/02/17/3239439/0/en/Portnoy-Law-Firm-Announces-Class-Action-on-Behalf-of-agilon-health-inc-Investors.html · 2/17/2026-0.30
https://www.globenewswire.com/news-release/2026/02/17/3239436/0/en/Portnoy-Law-Firm-Announces-Class-Action-on-Behalf-of-Quantum-Corporation-Investors.html · 2/17/2026-0.50
https://www.prnewswire.com/news-releases/investor-alert-pomerantz-law-firm-investigates-claims-on-behalf-of-investors-of-zenas-biopharma-inc---zbio-302687073.html · 2/12/2026-1.00
https://www.prnewswire.com/news-releases/investor-alert-pomerantz-law-firm-investigates-claims-on-behalf-of-investors-of-zenas-biopharma-inc---zbio-302656943.html · 1/9/2026-1.00
https://www.investopedia.com/dow-jones-today-010526-11878921 · 1/5/2026-0.90
https://www.defenseworld.net/2025/12/25/zenas-biopharma-nasdaqzbio-sets-new-52-week-high-heres-what-happened.html · 12/25/2025+1.00
Zenas BioPharma, Inc. functions as a clinical-stage biopharmaceutical firm, concentrating on the creation and market introduction of innovative, immunology-based treatments. The company's primary investigational therapy is obexelimab, a distinctive bifunctional monoclonal antibody intended to address multiple diseases such as immunoglobulin G4-related disease, multiple sclerosis, systemic lupus erythematosus, and warm autoimmune hemolytic anemia. Its developmental portfolio also features ZB002, an anti-TNFa monoclonal antibody; ZB004, a cytotoxic T-lymphocyte-associated antigen 4-immunoglobulin fusion; ZB001, an anti-insulin-like growth factor-1 receptor monoclonal antibody; and ZB005, an anti-active complement component 1s monoclonal antibody. Established in 2019, the entity was formerly recognized as Zenas BioPharma (Cayman) Limited before adopting its current name, Zenas BioPharma, Inc., in August 2023. Its headquarters are located in Waltham, Massachusetts.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
